{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:52:40Z","timestamp":1790355160860,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Current treatments for progressive neurodegenerative disorders characterized by cognitive impairment either have limited efficacy or are lacking altogether. SDI-118 is a small molecule which modulates the activity of synaptic vesicle glycoprotein 2A (SV2A) in the brain and shows cognitive enhancing effects in a range of animal models of cognitive deficit.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This first-in-human study evaluated safety, tolerability, and pharmacokinetics\/pharmacodynamics of SDI-118 in single ascending oral doses up to 80\u00a0mg administered to 32 healthy male subjects. Brain target occupancy was measured in eight subjects using positron emission tomography with PET-ligand [<jats:sup>11<\/jats:sup>C]-UCB-J. Food effect was assessed in seven subjects. Mood state was regularly evaluated using standardized questionnaires, and resting state fMRI data were analyzed as exploratory objectives.<\/jats:p><jats:p><jats:bold>Key Results:<\/jats:bold> At all doses tested, SDI-118 was well tolerated and appeared safe. Adverse events were mainly dizziness, hypersomnia, and somnolence. All were mild in intensity and increased in frequency with increasing administered dose. No dose-limiting adverse reactions were observed at any dose. SDI-118 displayed a linear pharmacokinetic profile with no significant food effect. Brain penetration and target engagement were demonstrated by a dose-proportional SV2A occupancy.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Single oral doses of SDI-118 up to 80\u00a0mg were very well tolerated in healthy male subjects. Dose-proportional SV2A occupancy in the brain was demonstrated with brain imaging. Adverse effects in humans mainly occurred in higher dose ranges, with high occupancy levels, and were all mild and self-limiting. These data support further clinical exploration of the compound in patients with cognitive disorders.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>, identifier <jats:ext-link>NCT05486195<\/jats:ext-link><\/jats:p>","DOI":"10.3389\/fphar.2022.1066447","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:42:16Z","timestamp":1673934136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET\/fMRI assessment of target engagement"],"prefix":"10.3389","volume":"13","author":[{"given":"Wouter","family":"Botermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Savidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sunaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve M.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ramael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Cesura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"D\u2019Ostilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Gossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten M.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lodeweyckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Hoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","article-title":"The use of analogue scales in rating subjective feelings","volume":"47","author":"Bond","year":"1974","journal-title":"Br. J. Med. Psychol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1440.011","article-title":"The brain\u2019s default network: Anatomy, function, and relevance to disease","volume":"1124","author":"Buckner","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.tics.2006.11.004","article-title":"Self-projection and the brain","volume":"11","author":"Buckner","year":"2007","journal-title":"Trends Cogn. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1523\/JNEUROSCI.4521-08.2009","article-title":"SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis","volume":"29","author":"Chang","year":"2009","journal-title":"J. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1037\/1040-3590.7.1.80","article-title":"Short form of the profile of mood states (POMS-SF): Psychometric information","volume":"7","author":"Curran","year":"1995","journal-title":"Psychol. Assess."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1523\/JNEUROSCI.2699-05.2006","article-title":"Synaptic vesicle protein 2 enhances release probability at quiescent synapses","volume":"26","author":"Custer","year":"2006","journal-title":"J. Neurosci."},{"key":"B8","volume-title":"Guidelines on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products","year":"2007"},{"key":"B9","volume-title":"Estimating the maximum safe starting dose in initial clinical trials for Therapeutics in adult healthy volunteers","year":"2005"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/0271678X17724947","article-title":"Kinetic evaluation and test-retest reproducibility of [11C]-UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans","volume":"38","author":"Finnema","year":"2018","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/epi.14701","article-title":"A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers","volume":"60","author":"Finnema","year":"2019","journal-title":"Epilepsia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1073\/pnas.0308627101","article-title":"Default-mode network activity distinguishes Alzheimer\u2019s disease from healthy aging: Evidence from functional MRI","volume":"101","author":"Greicius","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fnins.2018.00770","article-title":"Default mode network complexity and cognitive decline in mild alzheimer's disease","volume":"12","author":"Grieder","year":"2018","journal-title":"Front. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.bbadis.2011.07.008","article-title":"Imaging the default mode network in aging and dementia","volume":"1822","author":"Hafkemeijer","year":"2012","journal-title":"Biochim. Biophys. Acta."},{"key":"B15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mcn.2019.02.001","article-title":"Synaptic vesicle protein 2A as a potential biomarker in synaptopathies","volume":"97","author":"Heurling","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41467-019-09562-7","article-title":"Lower synaptic density is associated with depression severity and network alterations","volume":"10","author":"Holmes","year":"2019","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00259-018-4119-8","article-title":"Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue","volume":"46","author":"Koole","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","article-title":"Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond","volume":"30","author":"L\u00f6scher","year":"2016","journal-title":"CNS Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14504","DOI":"10.1073\/pnas.2235925100","article-title":"Functional deactivations: Change with age and dementia of the alzheimer type","volume":"100","author":"Lustig","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","first-page":"740","article-title":"Brivaracetam UCB","volume":"6","author":"Malawska","year":"2005","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","article-title":"In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET","volume":"16","author":"Mecca","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B24","doi-asserted-by":"publisher","first-page":"117877","DOI":"10.1016\/j.neuroimage.2021.117877","article-title":"Synaptic density in healthy human aging is not influenced by age or sex: A 11C-UCB-J PET study","volume":"232","author":"Michiels","year":"2021","journal-title":"NeuroImage"},{"key":"B25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2967\/jnumed.115.168179","article-title":"Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain","volume":"57","author":"Nabulsi","year":"2016","journal-title":"J. Nucl. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41467-019-14122-0","article-title":"Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats","volume":"11","author":"Onwordi","year":"2020","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mcn.2004.12.011","article-title":"SV2A and SV2C contain a unique synaptotagmin-binding site","volume":"29","author":"Schivell","year":"2005","journal-title":"Mol. Cell. Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/brain.2012.0073","article-title":"Conn: A functional connectivity toolbox for correlated and anticorrelated brain networks","volume":"2","author":"Whitfield-Gabrieli","year":"2012","journal-title":"Brain Connect."},{"key":"B29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/35087000","article-title":"SV2 modulates the size of the readily releasable pool of secretory vesicles","volume":"3","author":"Xu","year":"2001","journal-title":"Nat. Cell. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/epi.13223","article-title":"Brivaracetam augments short-term depression and slows vesicle recycling","volume":"56","author":"Yang","year":"2015","journal-title":"Epilepsia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.seizure.2009.07.004","article-title":"Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission","volume":"18","author":"Yang","year":"2009","journal-title":"Seizure"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1523\/JNEUROSCI.4781-09.2010","article-title":"Cotrafficking of SV2 and synaptotagmin at the synapse","volume":"30","author":"Yao","year":"2010","journal-title":"J. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1066447\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:42:20Z","timestamp":1673934140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1066447\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.1066447"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1066447","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"article-number":"1066447"}}